MEREO BIOPHARMA GROUP PLC Other Comprehensive Income (Loss), Net of Tax
MEREO BIOPHARMA GROUP PLC (MREO) reported Other Comprehensive Income (Loss), Net of Tax of $286.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-11
- MEREO BIOPHARMA GROUP PLC other comprehensive income (loss), net of tax for the quarter ending 2026-06-30 was $286.00K, a 95.70% decline year-over-year.
- MEREO BIOPHARMA GROUP PLC other comprehensive income (loss), net of tax for the quarter ending 2026-03-31 was -$1.75M, a 149.11% decline year-over-year.
- MEREO BIOPHARMA GROUP PLC other comprehensive income (loss), net of tax for the quarter ending 2025-09-30 was -$2.27M, a 131.60% decline year-over-year.
- MEREO BIOPHARMA GROUP PLC other comprehensive income (loss), net of tax for the quarter ending 2025-06-30 was $6.65M, a 132840.00% increase year-over-year.
- MEREO BIOPHARMA GROUP PLC other comprehensive income (loss), net of tax for fiscal 2025 was $8.03M.
- MEREO BIOPHARMA GROUP PLC other comprehensive income (loss), net of tax for fiscal 2024 was -$1.36M, a 132.46% decline from fiscal 2023.
- MEREO BIOPHARMA GROUP PLC other comprehensive income (loss), net of tax for fiscal 2023 was $4.20M.
- MEREO BIOPHARMA GROUP PLC other comprehensive income (loss), net of tax for fiscal 2022 was -$10.66M.
| Period end | Other Comprehensive Income (Loss), Net of Tax 3 month | Other Comprehensive Income (Loss), Net of Tax 6 month | Other Comprehensive Income (Loss), Net of Tax 9 month | Other Comprehensive Income (Loss), Net of Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $286.00K 10-Q · filed 2026-08-11 | -$1.46M derived: sum of 2 quarters · filed 2026-08-11 | ||
| 2026-03-31 | -$1.75M 10-Q · filed 2026-08-11 | |||
| 2025-12-31 | $8.03M 10-K · filed 2026-03-19 | |||
| 2025-09-30 | -$2.27M 10-Q · filed 2025-11-10 | $4.38M derived: sum of 2 quarters · filed 2026-08-11 | $7.94M derived: sum of 3 quarters · filed 2026-08-11 | |
| 2025-06-30 | $6.65M 10-Q · filed 2026-08-11 | $10.21M derived: sum of 2 quarters · filed 2026-08-11 | ||
| 2025-03-31 | $3.56M 10-Q · filed 2026-08-11 | |||
| 2024-12-31 | -$1.36M 10-K · filed 2026-03-19 | |||
| 2024-09-30 | $7.17M 10-Q · filed 2025-11-10 | $7.18M derived: sum of 2 quarters · filed 2025-11-10 | $6.38M derived: sum of 3 quarters · filed 2025-11-10 | |
| 2024-06-30 | $5.00K 10-Q · filed 2025-11-10 | -$793.00K derived: sum of 2 quarters · filed 2025-11-10 | ||
| 2024-03-31 | -$798.00K 10-Q · filed 2025-11-10 | |||
| 2023-12-31 | $4.20M 10-K · filed 2025-03-26 | |||
| 2023-09-30 | -$3.58M 10-Q · filed 2024-11-12 | -$2.18M derived: sum of 2 quarters · filed 2024-11-12 | $99.00K derived: sum of 3 quarters · filed 2024-11-12 | |
| 2023-06-30 | $1.40M 10-Q · filed 2024-11-12 | $3.68M derived: sum of 2 quarters · filed 2024-11-12 | ||
| 2023-03-31 | $2.28M 10-Q · filed 2024-11-12 | |||
| 2022-12-31 | -$10.66M 10-K · filed 2024-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |